Resistant Hypertension. An Overview of Evaluation and Treatment

Journal of the American College of Cardiology

Volumn 52, Issue 22, 2008, Pages 1749-1757

  Sarafidis, Pantelis A ^a   Bakris, George L ^b  

^a AHEPA UNIVERSITY HOSPITAL   (Greece)

^b Section of Endocrinology Diabetes and Metabolism   (United States)

Author keywords

evaluation; management; resistant hypertension; treatment

Indexed keywords

ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; AMLODIPINE PLUS BENAZEPRIL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANOREXIGENIC AGENT; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUMETANIDE; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DECONGESTIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ERYTHROPOIETIN; FUROSEMIDE; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOOP DIURETIC AGENT; LOSARTAN; NONSTEROID ANTIINFLAMMATORY AGENT; RENIN INHIBITOR; THIAZIDE DIURETIC AGENT; TORASEMIDE; UNINDEXED DRUG; VERAPAMIL;

ALCOHOL CONSUMPTION; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HEALTH EDUCATION; HEART INFARCTION; HUMAN; HYPERTENSION; KIDNEY DISEASE; LIFESTYLE MODIFICATION; MEDICATION ERROR; NATRIURESIS; OBESITY; OPTIMAL DRUG DOSE; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENESCENCE; SIDE EFFECT; SLEEP APNEA SYNDROME; SODIUM RESTRICTION; SODIUM RETENTION; THERAPY RESISTANCE; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION; WHITE COAT HYPERTENSION;

ALCOHOL DRINKING; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; CALCIUM CHANNEL BLOCKERS; DIURETICS; DRUG RESISTANCE; HUMANS; HYPERTENSION; OBESITY; PATIENT COMPLIANCE; PREVALENCE; RISK FACTORS; SODIUM, DIETARY; TREATMENT FAILURE; UNITED STATES; WEIGHT LOSS;

EID: 56149084750     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.08.036     Document Type: Review

References (78)

1. Wolf-Maier K., Cooper R.S., Banegas J.R., et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 289 (2003) 2363-2369
2. Turnbull F., Neal B., Ninomiya T., et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 336 (2008) 1121-1123
3. Lewington S., Clarke R., Qizilbash N., Peto R., and Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360 (2002) 1903-1913
4. Adler A.I., Stevens R.J., Manley S.E., Bilous R.W., Cull C.A., and Holman R.R. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63 (2003) 225-232
5. World Health Organization. World Health Report 2002: Reducing Risks, Promoting Healthy Life (2002), World Health Organization, Geneva, Switzerland
6. Ong K.L., Cheung B.M., Man Y.B., Lau C.P., and Lam K.S. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 49 (2007) 69-75
7. Wolf-Maier K., Cooper R.S., Kramer H., et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 43 (2004) 10-17
8. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 (2002) 2981-2997
9. Dahlof B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 995-1003
10. Pepine C.J., Handberg E.M., Cooper-DeHoff R.M., et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 290 (2003) 2805-2816
11. Chobanian A.V., Bakris G.L., Black H.R., et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 42 (2003) 1206-1252
12. Moser M., and Setaro J.F. Clinical practice. Resistant or difficult-to-control hypertension. N Engl J Med 355 (2006) 385-392
13. Calhoun D.A., Jones D., Textor S., et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 117 (2008) e510-e526
14. Pimenta E., Gaddam K.K., and Oparil S. Mechanisms and treatment of resistant hypertension. J Clin Hypertens (Greenwich) 10 (2008) 239-244
15. Kaplan N.M. Resistant hypertension. J Hypertens 23 (2005) 1441-1444
16. Sarafidis P.A., and Bakris G.L. State of hypertension management in the United States: confluence of risk factors and the prevalence of resistant hypertension. J Clin Hypertens (Greenwich) 10 (2008) 130-139
17. Sarafidis P.A., Li S., Chen S.C., et al. Hypertension awareness, treatment, and control in chronic kidney disease. Am J Med 121 (2008) 332-340
18. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 43 (2004) 1-290
19. Mancia G., Messerli F., Bakris G., Zhou Q., Champion A., and Pepine C.J. Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. Hypertension 50 (2007) 299-305
20. Pickering T.G., Hall J.E., Appel L.J., et al. Recommendations for blood pressure measurement in humans and experimental animals. Part 1: blood pressure measurement in humans. A statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation 111 (2005) 697-716
21. Verdecchia P., Schillaci G., Borgioni C., et al. White coat hypertension and white coat effect. Similarities and differences. Am J Hypertens 8 (1995) 790-798
22. Brown M.A., Buddle M.L., and Martin A. Is resistant hypertension really resistant?. Am J Hypertens 14 (2001) 1263-1269
23. Redon J., Campos C., Narciso M.L., Rodicio J.L., Pascual J.M., and Ruilope L.M. Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study. Hypertension 31 (1998) 712-718
24. Pierdomenico S.D., Lapenna D., Bucci A., et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens 18 (2005) 1422-1428
25. Caro J.J., Salas M., Speckman J.L., Raggio G., and Jackson J.D. Persistence with treatment for hypertension in actual practice. CMAJ 160 (1999) 31-37
26. Mazzaglia G., Mantovani L.G., Sturkenboom M.C., et al. Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens 23 (2005) 2093-2100
27. Van Wijk B.L., Klungel O.H., Heerdink E.R., and de Boer A. Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens 23 (2005) 2101-2107
28. Vrijens B., Vincze G., Kristanto P., Urquhart J., and Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 336 (2008) 1114-1117
29. Haynes R., Yao X., Degani A., et al. Interventions to enhance medication adherence. Cochrane Database Syst Rev (2005) CD000011
30. Takiya L.N., Peterson A.M., and Finley R.S. Meta-analysis of interventions for medication adherence to antihypertensives. Ann Pharmacother 38 (2004) 1617-1624
31. Singer G.M., Izhar M., and Black H.R. Goal-oriented hypertension management: translating clinical trials to practice. Hypertension 40 (2002) 464-469
32. Phillips L.S., Branch W.T., Cook C.B., et al. Clinical inertia. Ann Intern Med 135 (2001) 825-834
33. Trewet C.L., and Ernst M.E. Resistant hypertension: identifying causes and optimizing treatment regimens. South Med J 101 (2008) 166-173
34. Hyman D.J., and Pavlik V.N. Self-reported hypertension treatment practices among primary care physicians: blood pressure thresholds, drug choices, and the role of guidelines and evidence-based medicine. Arch Intern Med 160 (2000) 2281-2286
35. Oliveria S.A., Lapuerta P., McCarthy B.D., L'Italien G.J., Berlowitz D.R., and Asch S.M. Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med 162 (2002) 413-420
36. O'Brien E., Asmar R., Beilin L., et al. Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. J Hypertens 23 (2005) 697-701
37. Grossman E., and Messerli F.H. Secondary hypertension: interfering substances. J Clin Hypertens (Greenwich) 10 (2008) 556-566
38. Johnson A.G., Nguyen T.V., and Day R.O. Do nonsteroidal anti-inflammatory drugs affect blood pressure?. A meta-analysis. Ann Intern Med 121 (1994) 289-300
39. Conlin P.R., Moore T.J., Swartz S.L., et al. Effect of indomethacin on blood pressure lowering by captopril and losartan in hypertensive patients. Hypertension 36 (2000) 461-465
40. Bakris G.L., and Kern S.R. Renal dysfunction resulting from NSAIDs. Am Fam Physician 40 (1989) 199-204
41. Whelton A., White W.B., Bello A.E., Puma J.A., and Fort J.G. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or = 65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 90 (2002) 959-963
42. Graves J.W., Bloomfield R.L., and Buckalew Jr. V.M. Plasma volume in resistant hypertension: guide to pathophysiology and therapy. Am J Med Sci 298 (1989) 361-365
43. Nishizaka M.K., Pratt-Ubunama M., Zaman M.A., Cofield S., and Calhoun D.A. Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension. Am J Hypertens 18 (2005) 805-812
44. Vollmer W.M., Sacks F.M., Ard J., et al. Effects of diet and sodium intake on blood pressure: subgroup analysis of the DASH-sodium trial. Ann Intern Med 135 (2001) 1019-1028
45. Bramlage P., Pittrow D., Wittchen H.U., et al. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens 17 (2004) 904-910
46. Cushman W.C., Ford C.E., Cutler J.A., et al. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich) 4 (2002) 393-404
47. Morris M.J. Cardiovascular and metabolic effects of obesity. Clin Exp Pharmacol Physiol 35 (2008) 416-419
48. Sarafidis P.A. Obesity, insulin resistance and kidney disease risk: insights into the relationship. Curr Opin Nephrol Hypertens 17 (2008) 450-456
49. Wong C., and Marwick T.H. Obesity cardiomyopathy: pathogenesis and pathophysiology. Nat Clin Pract Cardiovasc Med 4 (2007) 436-443
50. Aucott L., Poobalan A., Smith W.C., Avenell A., Jung R., and Broom J. Effects of weight loss in overweight/obese individuals and long-term hypertension outcomes: a systematic review. Hypertension 45 (2005) 1035-1041
51. Calhoun D.A., Zaman M.A., and Nishizaka M.K. Resistant hypertension. Curr Hypertens Rep 4 (2002) 221-228
52. Yakovlevitch M., and Black H.R. Resistant hypertension in a tertiary care clinic. Arch Intern Med 151 (1991) 1786-1792
53. Garg J.P., Elliott W.J., Folker A., Izhar M., and Black H.R. Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypertens 18 (2005) 619-626
54. Anderson Jr. G.H., Blakeman N., and Streeten D.H. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens 12 (1994) 609-615
55. Taler S.J., Textor S.C., and Augustine J.E. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension 39 (2002) 982-988
56. Jamerson K., Bakris G.L., Dahlof B., et al. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press 16 (2007) 80-86
57. Black H.R., Elliott W.J., Grandits G., et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 289 (2003) 2073-2082
58. Handler J. Maximizing diuretic therapy in resistant hypertension. J Clin Hypertens (Greenwich) 9 (2007) 802-806
59. Ernst M.E., Carter B.L., Goerdt C.J., et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 47 (2006) 352-358
60. Khosla N., Chua D.Y., Elliott W.J., and Bakris G.L. Are chlorthalidone and hydrochlorothiazide equivalent blood-pressure-lowering medications?. J Clin Hypertens (Greenwich) 7 (2005) 354-356
61. Sarafidis P.A. Proteinuria: natural course, prognostic implications and therapeutic considerations. Minerva Med 98 (2007) 693-711
62. Medical News Today. FDA approves first combination therapy for initial use in patients with moderate to severe hypertension. http://www.medicalnewstoday.com/articles/89340.php Accessed August 15, 2008
63. Khanna A., Lefkowitz L., and White W.B. Evaluation of recent fixed-dose combination therapies in the management of hypertension. Curr Opin Nephrol Hypertens 17 (2008) 477-483
64. Dickson M., and Plauschinat C.A. Racial differences in medication compliance and healthcare utilization among hypertensive Medicaid recipients: fixed-dose vs free-combination treatment. Ethn Dis 18 (2008) 204-209
65. Saseen J.J., Carter B.L., Brown T.E., Elliott W.J., and Black H.R. Comparison of nifedipine alone and with diltiazem or verapamil in hypertension. Hypertension 28 (1996) 109-114
66. Gashti C.N., and Bakris G.L. The role of calcium antagonists in chronic kidney disease. Curr Opin Nephrol Hypertens 13 (2004) 155-161
67. Stergiou G.S., Makris T., Papavasiliou M., Efstathiou S., and Manolis A. Comparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy. J Hypertens 23 (2005) 883-889
68. Yusuf S., Teo K.K., Pogue J., et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358 (2008) 1547-1559
69. Mann J.F., Schmieder R., McQueen M., et al. Renal outcomes with telmisartan, ramipril, or both in people at high vascular risk: results from a multicenter, randomised, double-blind, controlled trial. Lancet 372 (2008) 547-553
70. Oparil S., Yarows S.A., Patel S., Fang H., Zhang J., and Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 370 (2007) 221-229
71. Pratt-Ubunama M.N., Nishizaka M.K., Boedefeld R.L., Cofield S.S., Harding S.M., and Calhoun D.A. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest 131 (2007) 453-459
72. Nishizaka M.K., Zaman M.A., and Calhoun D.A. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 16 (2003) 925-930
73. Chapman N., Dobson J., Wilson S., et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 49 (2007) 839-845
74. Pitt B., Reichek N., Willenbrock R., et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 108 (2003) 1831-1838
75. Eide I.K., Torjesen P.A., Drolsum A., Babovic A., and Lilledahl N.P. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 22 (2004) 2217-2226
76. Calhoun D.A. Resistant or difficult-to-treat hypertension. J Clin Hypertens (Greenwich) 8 (2006) 181-186
77. Nakov R., Pfarr E., and Eberle S. Darusentan: an effective endothelin A receptor antagonist for treatment of hypertension. Am J Hypertens 15 (2002) 583-589
78. Black H.R., Bakris G.L., Weber M.A., et al. Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study. J Clin Hypertens (Greenwich) 9 (2007) 760-769